Apexion Health PT-141 treatment vial
SEXUAL HEALTHPEPTIDE

MONTHLY SUPPLY · 1.75MG PER USE

PT-141

TREATMENT

Enhance arousal and desire centrally

SUPPORT

PT-141 acts on melanocortin receptors in the hypothalamus — the brain's arousal center — to enhance sexual desire and responsiveness through neural signaling rather than vascular mechanisms.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — SEXUAL HEALTH

DESIRE, ADDRESSED AT THE SOURCE.

Unlike PDE5 inhibitors that work on blood vessels, PT-141 (bremelanotide) acts centrally on melanocortin receptors in the hypothalamus and limbic system. It was originally investigated as a tanning peptide before researchers observed its potent effect on sexual arousal in both men and women. It works through neural signaling — desire, not mechanics — making it relevant regardless of vascular status.

Clinical Benefits

PT-141 SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    CENTRAL MECHANISM ENHANCES DESIRE AND AROUSAL

  2. 02.

    EFFECTIVE IN BOTH MEN AND WOMEN

  3. 03.

    ACTS INDEPENDENTLY OF VASCULAR MECHANISMS

  4. 04.

    ACTIVATES THE BRAIN'S OWN AROUSAL PATHWAYS

  5. 05.

    COMPLEMENTS OR REPLACES PDE5 INHIBITORS IN SOME PATIENTS

  6. 06.

    PHYSICIAN-PRESCRIBED NASAL ADMINISTRATION

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

HSDD Treatment Response

Meaningful Benefit ~25% in RECONNECT trials25%
SSE Increase Modest gain per month15%
Onset (median) 30 min post-SC injection95%

Kingsberg et al., Obstet Gynecol 2019 (RECONNECT)

02 — Hormone Panel

Efficacy & Tolerability

MarkerWithoutWith Treatment
Nausea%
1.3
40.0+38.7
Flushing%
0.3
20.3+20.0
Headache%
1.9
11.3+9.4
FSFI Desirepts
—
+0.3–0.4Modest

Modest efficacy — significant tolerability burden

RECONNECT: ~25% reporting benefit. 40% nausea rate (median 2.4 hr) is the major limitation. Contraindicated in uncontrolled HTN. On-demand only, max 8 doses/month.

Kingsberg et al., Obstet Gynecol 2019; FDA NDA 210557

03 — Protocol

As-Needed Dosing Protocol

First DoseDay 1
  • ›1.75 mg SC (abdomen/thigh)
  • ›Wait ≥45 min before activity
  • ›Assess nausea & tolerability
TitrationFirst 8 weeks
  • ›Max 1 dose/24 hours
  • ›Max 8 doses/month
  • ›Track efficacy & side effects
ContinuationWeek 8+
  • ›Continue if benefit shown
  • ›Discontinue if no improvement
  • ›Reassess every 3 months

NOT daily — strictly on-demand, max 8×/month

Inject ≥45 min before activity. Anti-emetic pre-treatment may help. Discontinue if no improvement at 8 weeks. Contraindicated: uncontrolled HTN, CVD.

All protocols physician-supervised and adjusted per individual labs.